A5017078421- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Lung Cancer Treatments and Mutations
- Liver Diseases and Immunity
- BRCA gene mutations in cancer
- Pediatric Hepatobiliary Diseases and Treatments
- Economic and Financial Impacts of Cancer
- Long-Term Effects of COVID-19
- Soft tissue tumor case studies
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Ethics in Clinical Research
- HER2/EGFR in Cancer Research
- Autoimmune Neurological Disorders and Treatments
- Ovarian cancer diagnosis and treatment
- Social Media in Health Education
- Blood donation and transfusion practices
- Parvovirus B19 Infection Studies
Mayo Clinic Hospital
2023-2025
Mayo Clinic in Arizona
2024-2025
Mayo Clinic in Florida
2024-2025
WinnMed
2023-2025
Northeast Georgia Medical Center
2021-2023
Coney Island Hospital
2021
North Shore University Hospital
2021
Feinstein Institute for Medical Research
2021
General Hospital of Serres
2021
Glenbrook Hospital
2021
536 Background: The prognosis of advanced BTC remains poor. Although targeted agents have expanded late-line options, many patients (pts) become ineligible for these therapies after progressing on first-line treatment. Herein, we examined the real-world impact therapy survival in BTC. Methods: In this international collaborative study between Mayo Clinic (US) and National Cancer Center East (Japan), included pts with comprehensive tumor molecular profiling who had received at least 30 days...
277 Background: While HER2-targeted therapies benefit patients (pts) with advanced HER2-positive mCRC, the development of resistance remains inevitable. This study aims to explore landscape and frequency genetic alterations putatively associated acquired anti-HER2 therapy in mCRC. Methods: In this retrospective-multicenter international involving Mayo Clinic, Duke Cancer Center National Hospital East (Japan), we descriptively compared comprehensive genomic analyses from tissue or blood...
243 Background: HER2-amplified aCRC is associated with poor prognosis despite new anti-HER2 regimens. Insight on biomarkers that predict response to these therapies limited. This study aims evaluate whether baseline alterations in oncogenic drivers along the HER2 pathway therapy aCRC. Methods: In this international multi-center involving Mayo Clinic, Duke Cancer Institute and National Center Hospital East (Japan), we collected genomic from tissue or blood samples using next-generation...
634 Background: CAT is the second leading cause of cancer-related death, yet genetic underpinnings VTE risk in BTC remain underexplored. The evaluation based on Khorana score (KS), which limited to clinical parameters. Incorporation a genomic signature assessment may allow for individualized assessment. Methods: We collected data from consecutive patients (pts) with treated at Mayo Clinic Hospitals (Phoenix, Rochester, Jacksonville) between 1998-2024. Genomic profiling was conducted FFPEs...
556 Background: Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a rare and complex liver cancer with features of both carcinoma (HCC) cholangiocarcinoma (CCA), making its management challenging. This study aims to analyze the clinical characteristics, genomic profiles, treatment outcomes cHCC-CCA patients in real-world setting. Methods: We conducted retrospective analysis across three first-line groups: chemotherapy alone(Gemcitabine/Cisplatin, FOLFOX), HCC-directed...
628 Background: Biliary tract cancers (BTC) are aggressive malignancies with poor survival outcomes and limited treatment options. This study compared the epidemiological molecular differences of advanced BTC patients through a global collaboration involving Mayo Clinic National Cancer Center Hospital East. Methods: We included who underwent comprehensive tumor profiling received at least 30 days systemic therapy. Patients were grouped based on specific alterations. Overall (OS) was...
Biliary tract cancer (BTC) remains among the most challenging malignancies with a poor prognosis and limited treatment options, particularly in pretreated patients. As patients experience disease progression after first-line treatment, effective second-line subsequent treatments are required. Although addition of modified FOLFOX (fluorouracil, leucovorin, oxaliplatin) to active symptom control improved overall survival progressing advanced BTC despite gemcitabine plus cisplatin its efficacy...
Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by autoantibodies directed at red blood cells. Patients typically present with and are diagnosed positive direct antiglobulin (DAT) test. AIHA subclassified into warm or cold based on antibodies involved depending their optimal temperature in which they react RBC antigens. Warm can be either primary (idiopathic) secondary etiology. Secondary causes associated malignancy, connective tissue inflammatory diseases, infections...
Infectious mononucleosis (IM) is an acute disease caused by Epstein-Barr virus (EBV) infection affecting adolescents and young adults. Clinically, IM presents with fever, lymphadenopathy, tonsillar pharyngitis. Guillain-Barré syndrome (GBS) has been reported as a possible rare complication of IM. IM-induced GBS known but rarely in the literature. Here, we describe case 19-year-old male no significant medical history who was diagnosed following EBV-associated A Caucasian presented from...
Gastrointestinal stromal tumors (GISTs) are rare with increasing incidence. GIST is the most common mesenchymal tumor of gastrointestinal tract involving elderly population a slow progression. It originates from interstitial cells Cajal. GISTs that develop outside and have no connections intestinal walls or serosal surfaces tubular organs referred to as extraintestinal (EGISTs). They similar morphological immunohistological characteristics GISTs. Here, we describe unique case an extremely...
Paraneoplastic rheumatic disorder (RD) is a that may present before, concurrent with, or after the diagnosis of malignancy. RDs are clinical expression occult cancer not directly related to tumor metastasis and manifests as rheumatoid symptoms. The RD determined by organ system affected articular, muscular, cutaneous, vascular, miscellaneous Each case challenging diagnose because with similar symptoms common disorder. Of note, majority cases have minimal responsiveness no standard treatment....
412 Background: Previously we have reported comparative effectiveness data regarding survival of first line (1L) treatment options in mRCC. However, it is not known how the life-prolonging frontline combinations compare to patient-reported outcomes. Methods: Electronic databases including MEDLINE and EMBASE were searched from each database’s inception through July 1 st 2023. Phase III randomized controlled trials (RCTs) assessing 1L immune-checkpoint inhibitor (ICI) combination therapies for...
Post-coronavirus disease 2019 (COVID-19) syndrome derives from lingering symptoms after an acute COVID-19 infection. Palpitation was one of the most common post-COVID-19 that correlated with objective data such as persisting sinus tachycardia; but to our best knowledge, there is a scarcity research regarding association and tachycardia in post-acute setting. Therefore, purpose identify if between infection phase, namely (PCT) other than inappropriate (IST) postural orthostatic (POTS).
BACKGROUNDThe TOPAZ-1 phase III trial demonstrated a survival advantage with durvalumab, an anti-programmed death cell ligand 1 (anti-PD-L1), when used gemcitabine and cisplatin for patients advanced biliary tract cancer. In order to gain broader understanding of the efficacy tolerability this new combination in real-world setting we performed worldwide multicenter retrospective analysis investigate safety first-line standard treatment.METHODSThe analyzed population included unresectable,...
Abstract Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess efficacy of cisplatin-gemcitabine-durvalumab (CGD) population comparable that reported phase 3 trial. Methods The cohort included BTC who underwent on primary tumor, experienced disease occurring ≤6 or >6 end adjuvant therapy started CGD. objectives overall...